Subsequent thrombotic outcomes in patients with ischemic stroke with antiphospholipid antibody positivity

Jung Yoon Pyo, Seung Min Jung, Sang Won Lee, Jason Jungsik Song, Soo Kon Lee, YongBeom Park

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose: International consensus criteria for antiphospholipid syndrome (APS) require persistently positive antiphospholipid antibodies (aPL) and medium or high titers in association with clinical manifestations. However, the clinical relevance of persistence and titers of aPL in patients with stroke has not been identified. We aimed to investigate the risk of subsequent thrombotic events in patients with ischemic stroke with aPL positivity in terms of aPL status. Materials and Methods: We reviewed the medical records of 99 patients with ischemic stroke with at least one or more aPL-positivity (i.e., positivity for aCL, anti-β2-glycoprotein-1, and/or lupus anticoagulants). The patients were divided into two groups: “definite APS” who fulfilled the laboratory criteria and “indefinite APS” who fell short of the criteria. We compared the risk of subsequent thrombotic events between the two groups. Cox proportional hazards model and Kaplan-Meier survival curves were used for the analyses. Results: Of the 99 patients, 46 (46%) were classified as having definite APS and 53 (54%) as having indefinite APS. The mean follow- up was 51.6 months. Overall event numbers were 14 (30.4%) in definite APS and 16 (30.2%) in indefinite APS. Increased subsequent thrombotic events (hazard ratio 1.039; 95% confidence interval 0.449-2.404; p=0.930) and decreased time to thrombotic events (log-rank p=0.321) were not associated with aPL status. Conclusion: There was no increased risk of subsequent thrombotic events in ischemic stroke patients with definite APS, compared with those with indefinite APS.

Original languageEnglish
Pages (from-to)1128-1134
Number of pages7
JournalYonsei medical journal
Volume58
Issue number6
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Stroke
Lupus Coagulation Inhibitor
Kaplan-Meier Estimate
Proportional Hazards Models
Medical Records
Glycoproteins
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Pyo, Jung Yoon ; Jung, Seung Min ; Lee, Sang Won ; Song, Jason Jungsik ; Lee, Soo Kon ; Park, YongBeom. / Subsequent thrombotic outcomes in patients with ischemic stroke with antiphospholipid antibody positivity. In: Yonsei medical journal. 2017 ; Vol. 58, No. 6. pp. 1128-1134.
@article{13e196fa1b7441a19782e89f24e8f370,
title = "Subsequent thrombotic outcomes in patients with ischemic stroke with antiphospholipid antibody positivity",
abstract = "Purpose: International consensus criteria for antiphospholipid syndrome (APS) require persistently positive antiphospholipid antibodies (aPL) and medium or high titers in association with clinical manifestations. However, the clinical relevance of persistence and titers of aPL in patients with stroke has not been identified. We aimed to investigate the risk of subsequent thrombotic events in patients with ischemic stroke with aPL positivity in terms of aPL status. Materials and Methods: We reviewed the medical records of 99 patients with ischemic stroke with at least one or more aPL-positivity (i.e., positivity for aCL, anti-β2-glycoprotein-1, and/or lupus anticoagulants). The patients were divided into two groups: “definite APS” who fulfilled the laboratory criteria and “indefinite APS” who fell short of the criteria. We compared the risk of subsequent thrombotic events between the two groups. Cox proportional hazards model and Kaplan-Meier survival curves were used for the analyses. Results: Of the 99 patients, 46 (46{\%}) were classified as having definite APS and 53 (54{\%}) as having indefinite APS. The mean follow- up was 51.6 months. Overall event numbers were 14 (30.4{\%}) in definite APS and 16 (30.2{\%}) in indefinite APS. Increased subsequent thrombotic events (hazard ratio 1.039; 95{\%} confidence interval 0.449-2.404; p=0.930) and decreased time to thrombotic events (log-rank p=0.321) were not associated with aPL status. Conclusion: There was no increased risk of subsequent thrombotic events in ischemic stroke patients with definite APS, compared with those with indefinite APS.",
author = "Pyo, {Jung Yoon} and Jung, {Seung Min} and Lee, {Sang Won} and Song, {Jason Jungsik} and Lee, {Soo Kon} and YongBeom Park",
year = "2017",
month = "11",
day = "1",
doi = "10.3349/ymj.2017.58.6.1128",
language = "English",
volume = "58",
pages = "1128--1134",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

Subsequent thrombotic outcomes in patients with ischemic stroke with antiphospholipid antibody positivity. / Pyo, Jung Yoon; Jung, Seung Min; Lee, Sang Won; Song, Jason Jungsik; Lee, Soo Kon; Park, YongBeom.

In: Yonsei medical journal, Vol. 58, No. 6, 01.11.2017, p. 1128-1134.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Subsequent thrombotic outcomes in patients with ischemic stroke with antiphospholipid antibody positivity

AU - Pyo, Jung Yoon

AU - Jung, Seung Min

AU - Lee, Sang Won

AU - Song, Jason Jungsik

AU - Lee, Soo Kon

AU - Park, YongBeom

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose: International consensus criteria for antiphospholipid syndrome (APS) require persistently positive antiphospholipid antibodies (aPL) and medium or high titers in association with clinical manifestations. However, the clinical relevance of persistence and titers of aPL in patients with stroke has not been identified. We aimed to investigate the risk of subsequent thrombotic events in patients with ischemic stroke with aPL positivity in terms of aPL status. Materials and Methods: We reviewed the medical records of 99 patients with ischemic stroke with at least one or more aPL-positivity (i.e., positivity for aCL, anti-β2-glycoprotein-1, and/or lupus anticoagulants). The patients were divided into two groups: “definite APS” who fulfilled the laboratory criteria and “indefinite APS” who fell short of the criteria. We compared the risk of subsequent thrombotic events between the two groups. Cox proportional hazards model and Kaplan-Meier survival curves were used for the analyses. Results: Of the 99 patients, 46 (46%) were classified as having definite APS and 53 (54%) as having indefinite APS. The mean follow- up was 51.6 months. Overall event numbers were 14 (30.4%) in definite APS and 16 (30.2%) in indefinite APS. Increased subsequent thrombotic events (hazard ratio 1.039; 95% confidence interval 0.449-2.404; p=0.930) and decreased time to thrombotic events (log-rank p=0.321) were not associated with aPL status. Conclusion: There was no increased risk of subsequent thrombotic events in ischemic stroke patients with definite APS, compared with those with indefinite APS.

AB - Purpose: International consensus criteria for antiphospholipid syndrome (APS) require persistently positive antiphospholipid antibodies (aPL) and medium or high titers in association with clinical manifestations. However, the clinical relevance of persistence and titers of aPL in patients with stroke has not been identified. We aimed to investigate the risk of subsequent thrombotic events in patients with ischemic stroke with aPL positivity in terms of aPL status. Materials and Methods: We reviewed the medical records of 99 patients with ischemic stroke with at least one or more aPL-positivity (i.e., positivity for aCL, anti-β2-glycoprotein-1, and/or lupus anticoagulants). The patients were divided into two groups: “definite APS” who fulfilled the laboratory criteria and “indefinite APS” who fell short of the criteria. We compared the risk of subsequent thrombotic events between the two groups. Cox proportional hazards model and Kaplan-Meier survival curves were used for the analyses. Results: Of the 99 patients, 46 (46%) were classified as having definite APS and 53 (54%) as having indefinite APS. The mean follow- up was 51.6 months. Overall event numbers were 14 (30.4%) in definite APS and 16 (30.2%) in indefinite APS. Increased subsequent thrombotic events (hazard ratio 1.039; 95% confidence interval 0.449-2.404; p=0.930) and decreased time to thrombotic events (log-rank p=0.321) were not associated with aPL status. Conclusion: There was no increased risk of subsequent thrombotic events in ischemic stroke patients with definite APS, compared with those with indefinite APS.

UR - http://www.scopus.com/inward/record.url?scp=85032011851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032011851&partnerID=8YFLogxK

U2 - 10.3349/ymj.2017.58.6.1128

DO - 10.3349/ymj.2017.58.6.1128

M3 - Review article

VL - 58

SP - 1128

EP - 1134

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -